FreeAgent acquired by RBS for £53 million
RBS has announced its intention to acquire our client FreeAgent for £53m. This is the first time since the 2008 crisis that RBS acquires a business. Quoted on AIM since November 2016 FreeAgent is a provider
Summit Therapeutics raises £15.0m
Summit Therapeutics plc, the Oxford based drug discovery and development company advancing therapies for rare and infectious diseases, announced today that it has raised £15 million. The Placing, which was oversubscribed, was conducted by means of
2018 Extel survey
We at N+1 Singer are very proud of our Research output and we’ve listed below some of our achievements. We are grateful for the ongoing support of our institutional clients in internal and external surveys and
[Video] Pharmaceutical Services – Structural growth in a complex landscape
Please click on the video below to hear our analysts present the main themes of their latest Pharmaceutical Services sector report. To receive the full sector note, email enquiry@n1singer.com
Theresa May’s Housing Speech and (overblown) Help to Buy concerns
The weekend saw a flurry of press articles describing the onset of Help to Buy interest payments as a “ticking time bomb”, rhetoric which we consider to be overblown. This was followed by yesterday’s housing speech
Alantra announces record net profit for 2017
N+1 Singer’s largest shareholder Alantra, the global investment banking and asset management firm, with offices across Europe, the US, Asia and Latin America,announced that it generated a record net profit of €30.2 million and achieved growth
